RxDoctor Payments Data

Michaele Brown, MD

Internal Medicine · Smyrna, GANPI 1609987056

Payments from drug & device makers

$5,023in general payments, 2019–2025

Across 315 payments — averaging $15.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$622
  • AbbVie$520
  • Boehringer Ingelheim$508
  • Novo Nordisk$495
  • Amgen$444
  • AstraZeneca$422
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$5,007100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,023 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$50,054
Medicare patients
171
Services billed
508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$69,012
JanuviaSitagliptin Phosphate39$59,399
JardianceEmpagliflozin32$46,742
RybelsusSemaglutide28$45,841
EliquisApixaban30$30,571
MounjaroTirzepatide25$30,367
TradjentaLinagliptin19$21,009
ProliaDenosumab12$20,959
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$16,538
MyrbetriqMirabegron23$15,919
Breo ElliptaFluticasone/Vilanterol22$13,532
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$6,873
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$4,280
Desloratadine72$2,755
Levothyroxine Sodium260$2,708

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$495$114,85379 claims
Boehringer IngelheimJardiance, Tradjenta$508$67,75151 claims
MerckJanuvia$121$59,39939 claims
PfizerEliquis$239$30,57130 claims
Lilly USA, LLCMounjaro$622$30,36725 claims
GSKTrelegy Ellipta, Breo Ellipta$264$30,07042 claims
AmgenProlia$444$20,95912 claims
Astellas Pharma US IncMyrbetriq$222$15,91923 claims
AbbVieSynthroid$520$1,57519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Smyrna

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →